Scientists found that an arthritis drug produces 54% remission in treatment-resistant depression by targeting the immune system instead of brain chemicals
One in three people with depression does not get better on antidepressants. They try one drug, then another, adjust doses, add medications, and still carry the same weight. The medical system calls this treatment-resistant depression, and it has represented one of psychiatry’s most stubborn unsolved problems for decades. The drugs that exist target brain chemicals. For a third of patients, targeting brain chemicals is not enough.
A randomized controlled clinical trial published in JAMA Psychiatry on May 20, 2026, led by researchers at the University of Bristol and University of Cambridge, just offered the most concrete clinical evidence yet for why that might be true. In a subset of depressed patients, the depression is not primarily a brain chemical problem. It is an immune system problem. And when researchers treated the immune system instead of the brain, 54% of patients who had failed to respond to standard antidepressants went into remission.
The drug they used was not a psychiatric medication. It was tocilizumab, an arthritis drug.
The Inflammation Signal in the Blood
The biological case for an immune-based subtype of depression has been building for years. Research has consistently found that approximately one in three people with depression carry elevated levels of inflammatory markers in their blood, including C-reactive protein and a specific cytokine called interleukin-6, or IL-6. Cytokines are the immune system’s chemical messengers, proteins that coordinate the body’s inflammatory response to infection, injury, and stress.
IL-6 is a particularly important actor in this story. It is a keystone inflammatory cytokine that drives systemic inflammation across multiple organ systems and crosses the blood-brain barrier in ways that directly affect the neural tissue responsible for mood regulation. Elevated IL-6 in the bloodstream is associated with reduced hippocampal volume, altered serotonin metabolism, and disruption of the prefrontal circuits involved in emotional regulation. It does not merely accompany depression. The evidence increasingly suggests that in a specific subset of patients, it is causing it.
The Bristol team, led by Éimear Foley and senior researcher Golam Khandaker, had spent years building the causal case for this relationship using Mendelian randomization, a genetic research method that uses naturally occurring genetic variations in large populations to test whether a biological factor actually causes an outcome or merely correlates with it. Their genetic analyses pointed consistently toward IL-6 as a causal contributor to depression, not just a marker of it. That evidence gave them the scientific justification to test what would happen if they blocked it directly in depressed patients.
The Trial
The proof-of-concept trial enrolled 30 adults with moderate to severe depression who had not responded adequately to standard antidepressant treatments. All participants had elevated inflammatory markers at baseline, confirming they belonged to the inflamed subtype of depression that the biological hypothesis predicted would respond to immunotherapy.
Participants were randomized in a double-blind fashion to receive either tocilizumab or a saline placebo by intravenous infusion. Tocilizumab works by blocking the IL-6 receptor, preventing IL-6 from binding and triggering its downstream inflammatory cascade. It is already approved and widely used for rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome. Its safety profile in those conditions is well characterized, which is one reason the Bristol team chose it as the vehicle for testing the IL-6 hypothesis in depression.
The results across the four-week follow-up period were striking. Compared with placebo, participants who received tocilizumab showed significant reductions in depression symptoms, anxiety, and fatigue, alongside improvements in overall quality of life. The clinical remission rate of 54% in the treatment group represents a response that standard antidepressants rarely achieve in this population, patients who have already failed to respond to conventional treatment and who represent some of the most difficult cases in psychiatric practice.
“Current drug treatments for depression are solely based on targeting chemicals in the brain, such as serotonin, norepinephrine, and dopamine,” Foley said. The trial provides the first direct clinical evidence that for patients whose depression is linked to immune dysregulation, targeting the immune pathway rather than the neurotransmitter pathway produces meaningful therapeutic benefit.
What the 54% Number Actually Means
The remission rate requires careful framing because the trial was small and the participants were not randomly selected from the general depression population. They were specifically chosen because they had elevated inflammatory markers, meaning the trial was testing the hypothesis that this specific subgroup responds to immunotherapy rather than that all depressed people would.
This selectivity is a feature, not a limitation. It is the foundation of what Khandaker called stratified or precision psychiatry, a model in which patients are matched to treatments based on their individual biological profile rather than receiving the same pharmacological approach regardless of underlying mechanism.
The failure rate of antidepressants in the general depression population is substantial not because the drugs do not work, but because they are applied uniformly to a condition that has multiple distinct biological subtypes. A serotonin-targeting drug is not addressing the problem in the third of patients whose depression is driven by chronic immune activation. Tocilizumab, conversely, is specifically designed to interrupt the inflammatory pathway that evidence increasingly implicates in exactly that subgroup.
The 54% remission rate in treatment-resistant patients with elevated inflammation is a meaningful signal because this is the hardest population to treat. These are people who have already failed standard care. Achieving remission in more than half of them by switching from a brain-chemical target to an immune target suggests the mismatch between treatment mechanism and biological cause has been driving their non-response all along.
Depression as an Immune Disorder
The Bristol trial builds on a body of evidence that has been accumulating for over a decade but has struggled to shift clinical practice, partly because the infrastructure for measuring inflammatory subtypes of depression in routine clinical settings does not yet exist. Blood tests for C-reactive protein and IL-6 are available and inexpensive, but they are not part of standard depression assessment protocols in most healthcare systems. Psychiatrists do not routinely order inflammation panels when evaluating a new depression case.
That practice gap is what the Bristol team is trying to close by moving from biological hypothesis to clinical trial evidence. The previous articles written about depression on your blog documented the gut bacterium producing inflammatory molecules linked to depression, the specific brain cells showing disrupted gene regulation in depressed tissue, and the serotonin pathway’s failure to account for a significant proportion of treatment outcomes. The Bristol trial is the clinical culmination of that biological argument: a randomized controlled study in humans showing that treating inflammation directly, in patients selected for having elevated inflammation, produces remission in people for whom the serotonin approach did not work.
Khandaker described the long-term ambition as transformative if the larger phase III trial confirms these results. A blood test. An IL-6 level. A treatment decision based on biology rather than trial and error across multiple antidepressant classes over months or years. For the one in three depressed people with elevated inflammatory markers, that pathway would represent a fundamentally different clinical experience than the one they have currently.
The Next Step
The phase III trial is the immediate priority. Thirty participants is sufficient to establish proof of concept and justify proceeding, but it is not sufficient to guide prescribing. The larger trial will need to confirm that the remission signal holds at scale, establish the optimal dosing and infusion schedule, characterize which specific inflammatory profiles respond most reliably, and generate the safety data required for regulatory approval in a psychiatric indication.
Tocilizumab is not a risk-free drug. It suppresses immune function in ways that increase susceptibility to infection and require monitoring. Prescribing it for depression would require a risk-benefit calculation that only a larger trial with longer follow-up can properly inform.
But the direction of the evidence is no longer ambiguous. Depression is not one condition. Some of it is driven by serotonin system disruption. Some of it is driven by the hypothalamic-pituitary-adrenal stress axis. And some of it, measurably, is driven by the immune system sending an inflammatory signal that the brain converts into despair. For that subset, the drug that treats arthritis may eventually be the drug that treats depression.
Sources:
Foley, É.M., Turner, N., Margelyte, R., Jones, H.J., Kaser, M., Lewis, G., Jones, P.B., Khandaker, G.M. Interleukin 6 as a treatment target for depression: a proof-of-concept randomized clinical trial. JAMA Psychiatry, May 20, 2026. DOI: 10.1001/jamapsychiatry.2026.1053
neurosciencenews.com/immunotherapy-arthritis-il6-depression-30735
